Furthermore, findings from an in situ tumor model demonstrated that epirubicin effectively reduced the proliferation of U87-derived tumor tissues in situ (Fig. 7L), as well as downregulating the expression of KI67, PCNA, and GPX4 in the tissues (Fig. 7M). This evidence concerns the gene GPX4 and neoplasm.